Author(s):
Himani Devi, Navneet Kaur, Himanshu Kumar, Rohan Kumar
Email(s):
himanighildiyal72@gmail.com
DOI:
10.52711/0974-360X.2026.00379 
Address:
Himani Devi1*, Navneet Kaur2, Himanshu Kumar3, Rohan Kumar4
1Assistant Professor, School of Pharmacy and Research, Dev Bhoomi Uttarakhand University, Uttarakhand, India.
2-4Research Scholar School of Pharmacy and Research, Dev Bhoomi Uttarakhand University, Uttarakhand, India.
*Corresponding Author
Published In:
Volume - 19,
Issue - 6,
Year - 2026
ABSTRACT:
In this study, two novel L-tryptophan sulphonamide derivatives were synthesized by reacting L-tryptophan with benzene sulfonyl chloride (Sample 1) and 4 nitrobenzene sulfonyl chloride (Sample 2) under basic conditions in anhydrous pyridine at 60°C for 1–4 h. The resulting products were isolated, purified, and obtained as stable, non hygroscopic solid crystals. Incorporation of the electron-withdrawing nitro group in Sample 2 resulted in a light-yellow solid with an elevated melting point (172–174°C), compared to 163–165°C for Sample 1. Thin Layer Chromatography (TLC) analysis using silica gel and an ethyl acetate:hexane (7:3, v/v) mobile phase revealed Rf values of 0.42 for Sample 1 and 0.36 for Sample 2, reflecting the influence of the nitro substituent on compound polarity. FTIR spectroscopy confirmed the presence of characteristic functional groups—in both samples, peaks corresponding to C–H (alkene), C–O–C (alcoholic), aromatic, and C=C (alkene) vibrations were observed, with slight shifts attributable to the nitro group in Sample 2. UV–Vis spectroscopy showed distinct absorbance maxima: Sample 1 exhibited peaks at 270nm (A=3.30), 225nm (A=10.00), and 215nm (A=3.27); Sample 2 showed peaks at 290nm (A=2.93), 275nm (A=3.16), 235nm (A=10.00), 220nm (A=3.26), and 205nm (A=3.22). These results collectively confirm successful synthesis and structural characterization of the sulfonated L-tryptophan derivatives, with the nitro substituent significantly affecting their physical properties and spectroscopic behaviour.
Cite this article:
Himani Devi, Navneet Kaur, Himanshu Kumar, Rohan Kumar. Design, Synthesis, Characterization and Molecular Docking Studies of Novel Sulphonamide Derivatives as Potential Anticancer Therapeutics. Research Journal Pharmacy and Technology. 2026;19(6):2652-8. doi: 10.52711/0974-360X.2026.00379
Cite(Electronic):
Himani Devi, Navneet Kaur, Himanshu Kumar, Rohan Kumar. Design, Synthesis, Characterization and Molecular Docking Studies of Novel Sulphonamide Derivatives as Potential Anticancer Therapeutics. Research Journal Pharmacy and Technology. 2026;19(6):2652-8. doi: 10.52711/0974-360X.2026.00379 Available on: https://rjptonline.org/AbstractView.aspx?PID=2026-19-6-36
REFERENCE:
1. Alani BG, Salim KS, Mahedi AS, Al Temimi AA. Sulfonamide derivatives: synthesis and application. Int J Front Chem Pharm Res. 2024; 4(1): 1–15.
2. Al-Harbi SA, Alghamdi MA, Rauf MA, Al-Warthan AI. Sulfonamides: A review on recent progress in biological activities. Chem Cent J. 2018; 12(1): 35. doi:10.1186/s13065-018-0415-5
3. White R, Cooper R. Silver sulphadiazine: A review of the evidence. Wounds UK. 2005; 1(2): 51.
4. Lavanya R. Sulphonamides: A pharmaceutical review. Int J Pharm Sci Invention. 2017; 6(2): 1–3.
5. Seneca H. Long-acting sulfonamides in urinary tract infections. JAMA. 1966; 198(9): 975–80.
6. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000; 28(1): 235–42.
7. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6): 2070–5.
8. Jia Y, Juarez J, Li J, Manuia M, Niederst MJ, Tompkins C, et al. EGF816 Exerts Antitumor Effects in Non–Small Cell Lung Cancer by Irreversible EGFR Inhibition and Antagonism of the T790M and C797S Resistance Mutations. Cancer Discov. 2016; 6(12): 1368–85.
9. Schrödinger Release 2023-2: Maestro, Schrodinger, LLC, New York, NY, 2023.
10. Olsson MHM, Søndergaard CR, Rostkowski M, Jensen JH. PROPKA3: Consistent treatment of internal and surface residues in empirical pKa predictions. J Chem Theory Comput. 2011; 7(2): 525–37.
11. Perkin Elmer Informatics. ChemDraw Professional 20.0 User Guide. Cambridge, MA: PerkinElmer Informatics, Inc.; 2020.
12. Schrodinger Release 2023-2: LigPrep, Schrödinger, LLC, New York, NY, 2023.
13. Shelley JC, Cholleti A, Frye LL, Greenwood JR, Timlin MR, Uchimaya M. Epik: A software program for pKa prediction and protonation state generation for drug-like molecules. J Comput Aided Mol Des. 2007; 21(12): 681–91.
14. Lu C, Wu C, Ghoreishi D, Chen W, Wang L, Damm W, et al. OPLS4: Improving force field accuracy on challenging regimes of chemical space. J Chem Theory Comput. 2021; 17(7): 4291–300.
15. Schrodinger Release 2023-2: Glide, Schrödinger, LLC, New York, NY, 2023.
16. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic Acids Res. 2000; 28(1): 235–42.
17. Yun CH, Mengwasser KE, Toms AV, Woo MS, Greulich H, Wong KK, et al. The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008; 105(6): 2070–5.
18. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004; 47(7): 1739–49.
19. Schrödinger Release 2023-2: Glide, Schrödinger, LLC, New York, NY, 2023.
20. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: A new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004; 47(7): 1739–49.
21. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: A new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004; 47(7): 1750–9.
22. Cole JC, Murray CW, Nissink JWM, Taylor RD, Taylor R. Comparing protein–ligand docking programs is difficult. Proteins. 2005; 60(3): 325–32.
23. Schrödinger, LLC. The PyMOL Molecular Graphics System, Version 2.5. New York, NY; 2021.
24. Wiedemann B, Heisig A, Heisig P. Uncomplicated urinary tract infections and antibiotic resistance—epidemiological and mechanistic aspects. Antibiotics (Basel). 2014; 3(3): 341–52.
25. Zessel K, Mohring S, Hamscher G, Kietzmann M, Stahl J. Biocompatibility and antibacterial activity of photolytic products of sulfonamides. Chemosphere. 2014; 100: 167–74.
26. Tačić A, Nikolić V, Nikolic L, Savić I. Antimicrobial sulfonamide drugs. Adv Technol. 2017; 6(1): 58–71.
27. Pareek A, Rani P, Kishore D. A short review on: Sulphonamides. Int J Pharm Bio Sci. 2013; 4(1): 812–20.
28. Supuran CT. Carbonic anhydrase inhibitors and activators: Current developments, potential, and therapeutic applications. J Enzyme Inhib Med Chem. 2022; 37(1): 1482–96. doi:10.1080/14756366.2022.2097230
29. Al Hoque A, Guha C, Sepay N, Dey SP, Halder UC. Anti-COVID-19 sulfonamides: A DFT, docking and ADMET study. Coronaviruses. 2022; 3(1): 73–80.